Tags : HEC

Biosimilars

Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting

Shots: The companies collaborated to co-develop Insulin aspart while Lannett granted exclusive US commercialization rights of insulin aspart to HEC Lannett will fund the clinical development requirements and will manage the clinical & regulatory steps specific for the FDA’s approval while HEC continues to develop the product and related manufacturing infrastructure. Both companies will share […]Read More